Virtual compound screening and SAR analysis: method development and practical applications in the design of new serine and cysteine protease inhibitors

Virtual screening is an important tool in drug discovery that uses different computational methods to screen chemical databases for the identification of possible drug candidates. Most virtual screening methodologies are knowledge driven where the availability of information on either the nature of the target binding pocket or the type of ligand that is expect to bind is essential. In this regard, the information contained in X-ray crystal structures of protein-ligand complexes provides a detailed insight into the interactions between the protein and the ligand and opens the opportunity for further understanding of drug action and structure activity relationships at molecular level. Protein-ligand interaction information can be utilized to introduce target-specific interaction-based constraints in the design of focused combinatorial libraries. It can also be directly transformed into structural interaction fingerprints and can be applied in virtual screening to analyze docking studies or filter compounds. However, the integration of protein-ligand interaction information into two-dimensional compound similarity searching is not fully explored. Therefore, novel methods are still required to efficiently utilize protein-ligand interaction information in two-dimensional ligand similarity searching. Furthermore, application of protein-ligand interaction information in the interpretation of SARs at the ligand level needs further exploration. Thus, utilization of three-dimensional protein ligand interaction information in virtual screening and SAR analysis was the major aim of this thesis. The thesis is presented in two major parts. In the first part, utilization of three-dimensional protein-ligand interaction information for the development of a new hybrid virtual screening method and analysis of the nature of SARs in analog series at molecular level is presented. The second part of the thesis is focused on the application of different virtual screening methods for the identification of new cysteine and membrane-bound serine proteases inhibitors. In addition, molecular modeling studies were also applied to analyze the binding mode of structurally complex cyclic peptide inhibitors

METHODS DEVELOPMENT IN BIOLOGICAL MASS SPECTROMETRY: APPLICATION IN GLYCOPROTEOMICS

Proteomics refers to global characterization of the full set of proteins present in a biological sample. Various analytical disciplines contribute to proteomics but mass spectrometry became method of choice for analysis of complex protein samples. Mass spectrometry allows for high throughput analysis of the proteome but, moreover, it has the ability to acquire higher-order information such as post-translational modifications (PTM). Glycosylation is the most abundant PTM on eukaryotic proteins. This dissertation will focus on method development for structural proteomics that will be utilized to explain the glycoproteome of obligate intracellular protozoan parasite Toxoplasma gondii as a model system. Optimization of sample preparation is addressed in the first part of this dissertation. Sample preparation for mass spectrometry analysis is a critical step in the proteomics workflow because the quality and reproducibility of sample extraction and preparation significantly impacts the separation and identification capabilities of mass spectrometers. Also, there are problems unique to intracellular parasites as limited amount, host cell impurity and choice of the host. The additional obstacle is to extract only glycosylated proteins for which there is no one standard method. Here we report the optimal sample preparation method utilizing agarose bound Concanavalin A (Con A) beads to efficiently pull down glycoproteins, dialyze and analyze them using MuDPIT. This method was further enhanced by passing the non-retained protein fraction (first flow-through) through a second Con A column and then passing the second non-retained protein fraction (second flow-through) through the third Con A column (3 sequential pull-downs) yielding 394 benchmark proteins. Glycoproteome of Toxoplasma gondii is not yet fully understood. However, evidence suggests that glycosylation could be essential for cyst formation and maintenance which is characteristic of chronic stage of disease. The focus of the second part of dissertation is to better understand the differences in glycoproteomes of tachizoites and tissue cysts. Cyst proteins pulled down using optimized sample preparation method that do not appear in the tachyzoites pulldowns could be critical elements in the structural stability of the tissue cyst

Biophysical and Biochemical Screening Approaches for Antimicrobial Drug Discovery Targeting S. aureus ClpP

The discovery of antibacterial drugs has been among most significant achievements of mankind in saving millions of lives across the planet from infectious diseases. With rise in resistance to almost all existing chemotypes, the design of next generation novel antibiotics has become much more challenging and difficult. The early 21st century witnessed the advancement of multiple novel chemotypes during golden age of antibiotics however the pace of antibiotic drug discovery has slowed down tremendously, contributing to life threatening antimicrobial discovery void since 1980’s. Therefore the need to develop novel antibiotics with unique mechanism of action to leverage against multi drug resistance pathogens, is paramount. In this direction the Caseinolytic Protease P (ClpP) is an emerging drug discovery target with significant potential for treatment of recalcitrant biofilm forming infections from pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA) This dissertation highlights the ongoing efforts to facilitate the discovery of novel non peptidic ClpP activator compounds and improvement of pharmacological profile of existing ClpP targeting Acyldepsipeptides (ADEPs) series antibiotics. The chapter one discusses the history and synopsis of conventional antibiotics drug discovery screening approaches, and transitions to modern era structure or fragment based screening approaches. The merits and challenges of such approaches of targeting a well conserved bacterial protease (ClpP) are discussed along with dissertation aims toward development of biophysical and biochemical screening approaches. Chapter two discusses optimization of thermal shift assay as primary screening assay for ClpP and its utility toward screening of fragment collections and buffer conditions. Chapter three discussed the development of a site specific Fluorescence Polarization based FP probe based on ADEP scaffold and its utility as a robust high throughput capable primary screening assay for screening of diverse collections ranging from bioactives to fragments. Chapter four discusses development of a label free Surface Plasmon Resonance (SPR) based assay geared toward screening of fragment as well as in house small and large (ADEP analogs) series compounds in addition to determining full kinetics for lead prioritization. Chapter five discusses the results of multiple screening campaigns utilizing combination of above assays to generate multiple hits with superior ligand efficiency and chemical tractability. Chapter six concludes with analysis of the best of compounds among individual series or from screening campaigns and highlights effectiveness of above screening assays toward hit exploration along with outlook on anticipated challenges and future directions

High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis

The development of increasingly high-throughput and sensitive mass spectroscopy-based proteomic techniques provides new opportunities to examine the physiology and pathophysiology of many biologic fluids and tissues. The purpose of this study was to determine protein expression profiles of high-abundance synovial fluid (SF) proteins in health and in the prevalent joint disease osteoarthritis (OA). A cross-sectional study of 62 patients with early OA (n = 21), patients with late OA (n = 21), and control individuals (n = 20) was conducted. SF proteins were separated by using one-dimensional PAGE, and the in-gel digested proteins were analyzed by electrospray ionization tandem mass spectrometry. A total of 362 spots were examined and 135 high-abundance SF proteins were identified as being expressed across all three study cohorts. A total of 135 SF proteins were identified. Eighteen proteins were found to be significantly differentially expressed between control individuals and OA patients. Two subsets of OA that are not dependent on disease duration were identified using unsupervised analysis of the data. Several novel SF proteins were also identified. Our analyses demonstrate no disease duration-dependent differences in abundant protein composition of SF in OA, and we clearly identified two previously unappreciated yet distinct subsets of protein profiles in this disease cohort. Additionally, our findings reveal novel abundant protein species in healthy SF whose functional contribution to SF physiology was not previously recognized. Finally, our studies identify candidate biomarkers for OA with potential for use as highly sensitive and specific tests for diagnostic purposes or for evaluating therapeutic response

Ghrelin Processing and Maturation: Developing a Molecular-Level Framework for Hormone Activation and Biological Function

Ghrelin is a 28 amino acid hormone involved in appetite stimulation, maintenance of energy balance, and a range of other neuroendocrine functions. Over the course of its expression and maturation, proghrelin (the prohormone of ghrelin) undergoes a unique posttranslational modification whereby a serine side chain is esterified with octanoic acid. Proghrelin then undergoes subsequent proteolysis to yield ghrelin. This octanoylation modification has been demonstrated to be required for ghrelin to activate its cognate receptor. Since acylated ghrelin has been linked with a variety of disease states, ghrelin signaling is a prime target for inhibition and inhibitor development. Biochemical and structural studies of the enzyme responsible for ghrelin octanoylation, ghrelin O-acyltransferase (GOAT), have identified features required for recognition of ghrelin by GOAT. A majority of these studies have utilized peptide mimetics of the N-terminal sequence of ghrelin. However, the impact of downstream elements in ghrelin and its 94 amino acid precursor proghrelin remains to be fully defined. To investigate this, we have developed bacterial expression systems to explore the role of both ghrelin and C-terminal ghrelin in proghrelin’s biological activity and maturation. The work presented in this dissertation is the first instance of expression and structural characterization of human proghrelin and C-ghrelin, as well as an unidentified self-cleavage behavior which has implications in hormone maturation. In complementary studies to characterize ghrelin binding to GOAT, ghrelin peptide mimetics incorporating an amine-substituted Dap residue at the site of acylation provided a superior system for exploring the molecular requirements for ghrelin recognition by GOAT. These studies have identified previously unidentified binding contacts and provides a comprehensive model of peptide binding in the hGOAT active site. The work utilizing Dap-substituted peptides provides a comprehensive peptide scaffold for future inhibitor design for targeting ghrelin signaling

Synthetic, Sulfated, Lignin-Based Anticoagulants

Chemoenzymatically synthesized low molecular weight lignin polymers have been previously found to be potent inhibitors of a number of serine proteases via allosteric mechanisms targeting heparin binding sites. Herein, we describe the creation of synthetic sulfated β-O4 lignin (SbO4L) polymer, which is more homogenous compared to previous lignins with respect to its inter-monomeric linkage. SbO4L is a selective inhibitor of thrombin and plasmin. SbO4L was found to act via a unique mechanism targeting thrombin exosite 2 in a manner similar to platelet glycoprotein Ibα (GPIbα). Advanced hemostasis and thrombosis assays demonstrated that SbO4L acts via a dual mechanism: as an anticoagulant, by allosteric inhibition of thrombin catalysis; and as an antiplatelet agent, by competing with platelet GPIbα. These mechanisms are comparable in potency to low molecular weight heparins currently used in the market, indicating that targeting exosite 2 may yield clinically useful drugs in the future. Since the β-O4 type lignin was found to be selective for thrombin and plasmin, we hypothesized that other scaffolds from lignins could be potent inhibitors of other serine proteases. In particular, we screened a library of synthetic sulfated small molecules against factor XIa – an emerging target for prophylactic anticoagulation. Our search identified a sulfated benzofuran trimer (a mimic of β-5 type linkage found in lignins) as a potent inhibitor of factor XIa. Surprisingly, this inhibitor did not compete with heparin. A plausible binding site in the A3 domain of factor XIa was proposed by using molecular modeling techniques. The binding pose demonstrated good correlation with the structure activity data from in vitro studies. Further confirmation that the apple domains were required was proved by testing the trimer against recombinant catalytic domain. A 40-fold decrease in activity was observed. A temperature-dependant perrin plot demonstrated that factor XIa undergoes a large conformational change in the presence of the trimer, which is possibly converting the enzyme back into the zymogen-like shape. In general, the synthetic sulfated lignins can act as a useful foundation to develop anticoagulant, antiplatelet, and anti-inflammatory molecules in the future